Trevi Therapeutics Stock Surges as Analysts Predict Major Upside

Trevi Therapeutics shares are demonstrating remarkable momentum with a sustained upward trajectory that has captured market attention. In the latest trading session, the biopharmaceutical company’s stock advanced by 3.48%, closing at $11.01. This represents the sixth positive session within a ten-day trading period, highlighting consistent investor confidence. Trading activity occurred between $10.56 and $11.11 with elevated volume indicators suggesting significant institutional participation.

Market researchers have expressed strong conviction in Trevi’s prospects, with nine analytical firms collectively establishing a price target of $20.72. This projection indicates substantial growth potential of approximately 95% from current levels. The consensus rating stands at “Strong Buy,” reinforced by an average score of 1.25, reflecting expert confidence in the biotechnology firm’s long-term value Read more...